JP2007504213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504213A5 JP2007504213A5 JP2006525215A JP2006525215A JP2007504213A5 JP 2007504213 A5 JP2007504213 A5 JP 2007504213A5 JP 2006525215 A JP2006525215 A JP 2006525215A JP 2006525215 A JP2006525215 A JP 2006525215A JP 2007504213 A5 JP2007504213 A5 JP 2007504213A5
- Authority
- JP
- Japan
- Prior art keywords
- glutaminyl
- use according
- pharmaceutically acceptable
- acceptable salt
- thiazolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49953503P | 2003-09-02 | 2003-09-02 | |
| PCT/IB2004/003082 WO2005020983A2 (en) | 2003-09-02 | 2004-09-02 | Combination therapy for glycaemic control |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504213A JP2007504213A (ja) | 2007-03-01 |
| JP2007504213A5 true JP2007504213A5 (https=) | 2007-08-30 |
Family
ID=34272835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525215A Withdrawn JP2007504213A (ja) | 2003-09-02 | 2004-09-02 | 糖血症コントロールの処置のための併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060287251A1 (https=) |
| EP (1) | EP1663200A2 (https=) |
| JP (1) | JP2007504213A (https=) |
| KR (1) | KR20060119927A (https=) |
| CN (1) | CN1845731A (https=) |
| AU (1) | AU2004267955A1 (https=) |
| BR (1) | BRPI0413204A (https=) |
| CA (1) | CA2536432A1 (https=) |
| EA (1) | EA200600356A1 (https=) |
| IL (1) | IL173844A0 (https=) |
| MX (1) | MXPA06002127A (https=) |
| NO (1) | NO20061085L (https=) |
| WO (1) | WO2005020983A2 (https=) |
| ZA (1) | ZA200601770B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0526291D0 (en) * | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
| GB0623892D0 (en) * | 2006-11-29 | 2007-01-10 | Medical Res Council Technology | Assay |
| CN102933598A (zh) * | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| MX359329B (es) * | 2011-10-28 | 2018-09-25 | Sanofi Aventis Deutschland | Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| DE29924609U1 (de) * | 1999-05-28 | 2004-04-22 | Probiodrug Ag | Neue Effektoren von Dipeptidylpeptidase IV |
| EP1743655B1 (en) * | 2000-01-21 | 2014-06-25 | Novartis AG | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| CA2479812A1 (en) * | 2002-02-28 | 2003-09-04 | Prosidion Ltd. | Glutaminyl based dpiv inhibitors |
| ATE461212T1 (de) * | 2002-09-18 | 2010-04-15 | Prosidion Ltd | Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv) |
-
2004
- 2004-09-02 EP EP04769446A patent/EP1663200A2/en not_active Withdrawn
- 2004-09-02 BR BRPI0413204-1A patent/BRPI0413204A/pt not_active IP Right Cessation
- 2004-09-02 AU AU2004267955A patent/AU2004267955A1/en not_active Abandoned
- 2004-09-02 MX MXPA06002127A patent/MXPA06002127A/es not_active Application Discontinuation
- 2004-09-02 CA CA002536432A patent/CA2536432A1/en not_active Abandoned
- 2004-09-02 CN CNA2004800251945A patent/CN1845731A/zh active Pending
- 2004-09-02 KR KR1020067004354A patent/KR20060119927A/ko not_active Withdrawn
- 2004-09-02 JP JP2006525215A patent/JP2007504213A/ja not_active Withdrawn
- 2004-09-02 WO PCT/IB2004/003082 patent/WO2005020983A2/en not_active Ceased
- 2004-09-02 US US10/570,113 patent/US20060287251A1/en not_active Abandoned
- 2004-09-02 EA EA200600356A patent/EA200600356A1/ru unknown
-
2006
- 2006-02-21 IL IL173844A patent/IL173844A0/en unknown
- 2006-02-28 ZA ZA200601770A patent/ZA200601770B/en unknown
- 2006-03-06 NO NO20061085A patent/NO20061085L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI241185B (en) | Antidiabetic formulation | |
| AU2006292377B2 (en) | Use of a DPP-IV inhibitor to reduce hypoglycemic events | |
| KR100643833B1 (ko) | 인슐린 감작제 및 다른 항당뇨병 약제의 개선된 방출을위한 제약 조성물 | |
| Setter et al. | Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy | |
| JP2016501841A5 (https=) | ||
| JP2008517921A5 (https=) | ||
| JP2013227337A (ja) | Ｄｐｉｖインヒビターおよびメトホルミンまたはチアゾリジンジオンの組み合わせによる２型糖尿病の治療 | |
| JP2021523877A5 (https=) | ||
| JP2006515267A5 (https=) | ||
| US6780432B1 (en) | Core formulation | |
| JP2008517921A (ja) | Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤 | |
| KR20210005843A (ko) | Glp1r 작용제의 치료적 용도 | |
| US6296874B1 (en) | Core formulation comprising troglitazone and abiguanide | |
| Kiayias et al. | Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients | |
| JP2007504213A5 (https=) | ||
| US20030224046A1 (en) | Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent | |
| US6461639B2 (en) | Core formulation | |
| RU2012147449A (ru) | Способы использования диацереина в дополнительном лечении диабета | |
| MXPA06001629A (es) | Composicion nueva que comprende rosiglitazona y otro agente antidiabetico. | |
| AU2001257456B2 (en) | A core formulation | |
| MXPA04000180A (es) | Formulacion de nucleo que comprende hidrocloruro de pioglitazona y una biguanida. | |
| JP2004536841A (ja) | コア製剤 | |
| AU2001257456A1 (en) | A core formulation | |
| Jeong et al. | The effect of the taeguk gi-gong exercise on insulin resistance and blood glucose in patients with type II diabetes mellitus | |
| Salpeter et al. | Metformin does not increase risk for lactic acidosis or increase lactate levels in type 2 diabetes/COMMENTARY |